KIMIA BIOSCIENCES LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 46.1 INR | -0.04% |
|
-2.64% | +25.27% |
| Sales 2022 | 1.25B 15.01M | Sales 2023 | 1.29B 15.45M | Capitalization | 1.54B 18.48M |
|---|---|---|---|---|---|
| Net income 2022 | -37M -445K | Net income 2023 | -93M -1.12M | EV / Sales 2022 | 1.79 x |
| Net Debt 2022 | 452M 5.44M | Net Debt 2023 | 580M 6.97M | EV / Sales 2023 | 1.65 x |
| P/E ratio 2022 |
-48
x | P/E ratio 2023 |
-16.4
x | Employees | 241 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 7.83% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.04% | ||
| 1 week | -2.64% | ||
| Current month | -8.77% | ||
| 1 month | -12.89% | ||
| 3 months | +26.61% | ||
| 6 months | +23.92% | ||
| Current year | +25.27% |
1 week
45.51
52.00
1 month
44.5653.50
Current year
33.2058.40
1 year
31.9958.40
3 years
30.2065.80
5 years
19.0565.80
10 years
5.0076.50
| Managers | Title | Age | Since |
|---|---|---|---|
Sameer Goel
CEO | Chief Executive Officer | 49 | 16-03-28 |
Rakesh Chetani
DFI | Director of Finance/CFO | - | 23-09-06 |
Lakshay Prakash
CMP | Compliance Officer | - | 22-05-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sameer Goel
CEO | Chief Executive Officer | 49 | 16-03-28 |
Jagdeep Dhawan
BRD | Director/Board Member | 53 | 16-03-28 |
Richa Gupta
BRD | Director/Board Member | 43 | 16-04-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-23 | 46.1 | -0.04% | 215 |
| 24-05-22 | 46.12 | -2.41% | 69 |
| 24-05-21 | 47.26 | 0.00% | 2,404 |
| 24-05-18 | 47.26 | -4.89% | 632 |
| 24-05-17 | 49.69 | +4.94% | 152 |
Delayed Quote Bombay S.E., May 23, 2024 at 06:00 am EDT
More quotes
Kimia Biosciences Limited is an India-based company, which is engaged in the business of pharmaceutical products. The Company provides its products under various categories: Commercial Active Pharmaceutical Ingredients (APIs), Commercial KSMs, Intermediates & Reagents. The Company's Commercial-APIs products include acotiamide hydrochloride hydrate, azelnidipine, benfotiamine, benidipine hydrochloride, citicoline sodium, gliclazide, dapagliflozin propanediol monohydrate, levosulpiride, luliconazole, oxaceprol, prucalopride succinate, teneligliptin hydrobromide hydrate, vildagliptin, fimasartan trihydrate potassium, obeticholic acid and ursodeoxycholic acid. Its Commercial KSMs, Intermediates & Reagents products include Ethyl-2-Amino 1,3-Thiazole 4-Carboxylate, 2,4,5-Trimethoxy Benzoic Acid, Ethyl 2-(2,4,5-trimethoxybenzamido)-1,3-thiazole-4-carboxylate, Isopropyl 2-(3-Nitrobenzylidene) Acetoacetate, Choline phosphate chloride calcium, and more.
Sector
Pharmaceuticals
Calendar
2024-05-29
- Q4 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| +25.27% | 26.21M | |
| +37.74% | 723B | |
| +34.49% | 595B | |
| -2.07% | 369B | |
| +20.25% | 332B | |
| +2.99% | 282B | |
| +16.94% | 244B | |
| +9.71% | 208B | |
| -4.29% | 205B | |
| +7.43% | 166B |
- Stock Market
- Equities
- KIMIABL Stock
